On November 18, SELLAS Life Sciences Group Inc. rose 7.83% in Regular Trading, trading at $19.415 per share, with turnover of $51.1558 million.
The move coincided with continued market repricing after the company reported that galinpepimut-S met the primary endpoint in the Phase 3 REGAL trial in acute myeloid leukemia, while a brokerage also raised its price target to $40 from $30.
Earlier disclosures showed median overall survival of 24 months for treated patients versus 14.7 months for the control arm, with a 41% reduction in risk of death and no new safety issues. The company said it plans to discuss an accelerated filing strategy with the FDA and prepare a marketing application in H1 2027. Although SELLAS Life Sciences Group Inc. also announced a $150 million underwritten public offering, with an additional $22.5 million option for underwriters, the latest intraday rise suggests investors are refocusing on the Phase 3 clinical milestone.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments